News | August 08, 2025
Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Cenexi reports an EBITDA breakeven for the quarter
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The company received one observation in the Form-483
Revenue increased 11.4 per cent to Rs. 8,545 crore
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
Subscribe To Our Newsletter & Stay Updated
